July 5th ResultsInteresting that this news release was in the PM, usually results are not released until the AM.
Looks like a hit to Net Income on non-cash loss due to warrant mark to market. Lower Guidance on EGRIFTA is disappointing but mostly expected hence the share price drop from $3.70 to current levels. Great buying opportunity if Mr. Market continues to shake out weak shareholders who have not done their homework on Ibalizumab, which is worth north of $10 per share on its own. GLTA